Assays for parathyroid hormone and their use in patients with end-stage renal disease

被引：1

作者：

Goodman, WG ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Med Ctr, Dept Med, Div Nephrol,Sch Med, Los Angeles, CA 90095 USA

来源：

BLOOD PURIFICATION | 2003年 / 21卷 / 01期

关键词：

parathyroid hormone; assay; renal osteodystrophy; end-stage renal disease; bone disease;

D O I：

10.1159/000067857

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

New second-generation immunometric PTH assays have been developed. The assays measure full-length biologically active PTH(1-84) exclusively and do not detect amino-terminally-truncated PTH fragments, a feature that distinguishes them from first-generation immunometric PTH assays. Although few studies have been done thus far, second-generation immunometric PTH assays have not been shown to be superior to first-generation assays for the diagnostic assessment of patients with renal osteodystrophy. Plasma PTH levels obtained using first-generation-immunometric PTH assays continue to provide the most definitive guide to the management of renal bone disease because they are supported by abundant bone histology data. Additional work is needed to further characterize the utility of second-generation immunometric PTH assays as predictors of bone histology in patients with ESRD. Copyright (C) 2003 S. Karger AG, Basel.

引用

页码：118 / 123

页数：6

共 50 条

[1] Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions
Cantor, Tom
Yang, Zan
Caraiani, Nicolae
Ilamathi, Ekambaram
CLINICAL CHEMISTRY, 2006, 52 (09) : 1771 - 1776
[2] T-cell activation modified by parathyroid hormone (PTH) in patients with end-stage renal disease
Kaneko, T
Osono, E
Hayama, N
Lino, Y
Terashi, A
CLINICAL NEPHROLOGY, 1997, 48 (06) : 353 - 358
[3] CLINICAL-APPLICATIONS OF PARATHYROID-HORMONE IMMUNOASSAYS IN PATIENTS WITH END-STAGE RENAL-DISEASE
YOHAY, DA
QUARLES, LD
SEMINARS IN DIALYSIS, 1993, 6 (05) : 305 - 311
[4] Pathogenesis of parathyroid dysfunction in end-stage renal disease
Silver, J
ADVANCES IN RENAL REPLACEMENT THERAPY, 2002, 9 (03): : 159 - 167
[5] THE PREVALENCE AND INCIDENCE OF VERTEBRAL FRACTURES IN END-STAGE RENAL DISEASE AND THE ROLE OF PARATHYROID HORMONE
Jansz, Thijs
Goto, Namiko
Van Ballegooijen, Adriana
Willems, Hanna
Verhaar, Marianne
Van Jaarsveld, Brigit
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 11 - 11
[6] The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone
Jansz, T. T.
Goto, N. A.
van Ballegooijen, A. J.
Willems, H. C.
Verhaar, M. C.
van Jaarsveld, B. C.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (03) : 515 - 524
[7] The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone
T. T. Jansz
N. A. Goto
A. J. van Ballegooijen
H. C. Willems
M. C. Verhaar
B. C. van Jaarsveld
Osteoporosis International, 2020, 31 : 515 - 524
[8] Should activated vitamin D be used in patients with end-stage renal disease and low levels of parathyroid hormone?
Wolf, Myles
SEMINARS IN DIALYSIS, 2011, 24 (04) : 428 - 430
[9] Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease
Battistella, M.
Richardson, R. M. A.
Bargman, J. M.
Chan, C. T.
CLINICAL NEPHROLOGY, 2011, 76 (02) : 99 - 104
[10] Associations of parathyroid hormone levels and mineral parameters with heart rate variability in patients with end-stage renal disease
Zhang, Lei
Yang, Shaoyan
Chen, Jianling
Ma, Jinling
Ren, Yueqin
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (06) : 1079 - 1085

← 1 2 3 4 5 →